DTU Logo
Overview | 4-T | ACE | ADOPT | AFORRD | DREAM | EDIT | EXSCEL | FHS | GLINT | ISAT | LDS | NAVIGATOR | TECOS | UKPDS

Glucose Lowering in Non-diabetic hyperglycaemia Trial



GLINT is a multi-centre, randomised, double-blind, primary prevention trial comparing the effect of slow-release metformin with placebo on a macrovascular composite outcome in people with non-diabetic hyperglycaemia and high CVD risk in primary care

Study Objectives

The GLINT study aims to evaluate the effect of adding metformin to the usual care of participants with NDH on major macrovascular events. A secondary objectives of the study are to evaluate the effect of adding metformin to the usual care of participants with non-diabetic hyperglycaemia on:

Primary Endpoint

Composite endpoint defined as the time to the first occurrence after randomisation of any of:

Secondary Endpoints

Study Population

Study Treatments

Patients will be randomised to one of the following two regimens:

A 'Start low, Go slow' dose titration scheme will be used. By the third month post-randomisation, patients should be fully titrated and will be required to take three tablets a day.

Assessment Periods

Patients will attend a recruitment visit and will then be followed up via postal questionnaires. During the feasability study there will be two additional visits and additional assessments performed to assess drug adherence, changes in laboratory values and safety parameters.